Microbiome—Friend or Foe of Pancreatic Cancer?

Microbiome—Friend or Foe of Pancreatic Cancer?

Pancreatic ductal adenocarcinoma is one of the deadliest human neoplasms. Despite the development of new surgical and adjuvant therapies, the prognosis remains very poor, with the overall survival rate not exceeding 9%. There is now increasing evidence that the human microbiome, which is involved in...

Full description

Bibliographic Details
Main Authors: Jaroslaw Daniluk, Urszula Daniluk, Pawel Rogalski, Andrzej Dabrowski, Agnieszka Swidnicka-Siergiejko
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Journal of Clinical Medicine
Subjects:
pancreatic cancer
microbiome
inflammation
immunotherapy
Online Access:https://www.mdpi.com/2077-0383/10/23/5624

Similar Items

Similar Items